Market-Moving News for July 15th
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
11/1/2021 | $4.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00
LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy
Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00
4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)
4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)
4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)
RF Innovations' Apex 6 Generator aligns with specifications required for Autonomix's ablation system and facilitates ongoing developmentTransaction further reinforces Autonomix's FDA regulatory pathwayTHE WOODLANDS, TX, July 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed its previously announced transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator. T
- Reuters
SC 13D - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
EFFECT - Trump Media & Technology Group Corp. (0001849635) (Filer)
424B3 - Trump Media & Technology Group Corp. (0001849635) (Filer)
DEF 14A - Autonomix Medical, Inc. (0001617867) (Filer)
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure 100% of this responder group had clinically meaningful pain relief at 4-6 weeks post-procedure Trial remains on track to complete enrollment by year-end 2024 THE WOODLANDS, TX, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today annou
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City. Artelo's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024 at 7:00 AM Eastern Time. A webcast of
THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more informat